PAPMET (SWOG S1500)
PAPMET was the first randomised trial dedicated to papillary kidney cancer; cabozantinib held the disease back for longer than sunitinib, the previous default, while two more selective MET inhibitors did not.
Overview
Papillary renal cell carcinoma had been treated with drugs developed for clear cell disease. PAPMET, a SWOG-led randomised phase 2 trial, assigned 152 patients with metastatic papillary renal cell carcinoma, untreated or after one prior therapy, to sunitinib or to one of three MET-directed inhibitors: cabozantinib, crizotinib or savolitinib. The primary endpoint was progression-free survival against sunitinib.
The crizotinib and savolitinib arms were closed early for futility. Cabozantinib lengthened progression-free survival and produced more responses than sunitinib, and became the preferred single agent for papillary disease in guidelines, later joined by immunotherapy combinations tested in single-arm studies.
Similar pages
not linked directly; found by shared links- TrialCABONE
Shares Exelixis, Cabozantinib and the tag subtype-trials.
- TrialEXAM
Shares Exelixis, Cabozantinib and the tag subtype-trials.
- TrialCARMENA
Shares Sunitinib, Renal cell carcinoma and the tag subtype-trials.
- TrialCheckMate 025
Shares Renal cell carcinoma and the tag subtype-trials.
- TrialSavolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
Shares Papillary renal cell carcinoma, Savolitinib, Sunitinib, Renal cell carcinoma.
- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Papillary renal cell carcinoma, Savolitinib, Sunitinib, Renal cell carcinoma.
- TrialA Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va
Shares Exelixis, Cabozantinib.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Papillary renal cell carcinoma, Renal cell carcinoma.